Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy

Locally Advanced Breast Cancer Clinical Trial

Official title:

Select the Appropriate Population for Adding CDK4/6i to Neoadjuvant Endocrine Therapy in High Risk Early HR+/HER2-breast Cancer Based on Molecular Marker

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05809024
• Other study ID #: MA-BC-II-023
• Status: Recruiting
• Phase: Phase 4
• Start date: March 1, 2023
• Est. completion date: March 25, 2026

Study information

• Verified date: April 2023
• Source: Shandong Cancer Hospital and Institute
• Contact: yongsheng wang, MD
• Phone: +8613605409989
• Email: wangysh2008[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Select the appropriate population for adding CDK4/6 inhibitors therapy in high risk early HR+/HER2-breast cancer based on molecular detection

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: March 25, 2026
• Est. primary completion date: March 25, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Newly treated female patients, =18 and =75 years;

2. ECOG score 0-1;

3. Breast cancer following:

Histologically confirmed invasive breast cancer with primary tumor diameter >2 cm by standard evaluation methods.Tumor stage: cT2-cT4/cN0-cN3/cM0 (clinical phase II and III)

4. HR+/HER2- breast cancer confirmed by pathological examination, defined as: primary HR+/HER2- breast cancer performed by the pathology department of the Central Hospital;

5. Get hormone receptor status (ER and PR);

6. Major organ function following:

Complete blood count: Neutrophil (ANC) = 1.5×109/L; Platelet count (PLT) = 90×109/L; hemoglobin (Hb) =90 g/L; Blood Biochemistry: Total bilirubin (TBIL) = 2.5×ULN; Alanine aminotransferase (ALT) = 1.5×ULN; Aspartate aminotransferase (AST) = 1.5×ULN; Alkaline phosphatase = 2.5×ULN; Urea nitrogen (BUN) = 1.5×ULN; Creatinine (Cr) = 1.5×ULN; Twelve-lead electrocardiogram: Fridericia corrected QT Interval (QTcF) woman < 470 ms (QTcF=QT/(RR^1/3));

7. Woman who are not menopausal or have not been surgically sterilized agree to abstain from sex or use effective contraceptive methods for at least the duration of the study treatment and for 7 months after the last dosing;

8. Volunteer to participate in the study, sign informed consent, have good compliance and be willing to cooperate with follow-up.

Exclusion Criteria:

1. IV stage breast cancer or metastatic breast cancer;

2. Inflammatory breast cancer;

3. Any previous malignant tumor or previous anti-tumor therapy or radiotherapy were not allowed, excluding cured cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma;

4. Participate in other clinical trials;

5. Patients were not allowed who had undergone major non-breast cancer related surgery within 4 weeks prior to randomization or had not fully recovered from such surgery;

6. Patients were not allowed who had received blood transfusion or colony stimulating factor treatment within 2 weeks before randomization;

7. Patients were not allowed who allergic to drug components;

8. Patients were not allowed who had a history of immunodeficiency, including HIV positive, or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation;

9. Patients have heart disease were not allowed including: (1) angina pectoris; (2) medically treatable or clinically significant arrhythmias; (3) myocardial infarction; (4) heart failure; (5) any other heart disease that the investigator has determined is not suitable for participation in the study;

10. Pregnant and lactating women, fertile women who tested positive for baseline pregnancy tests, or fertile women who were unwilling to take effective contraceptive measures during the test period were not allowed;

11. Patients have concomitant diseases that endanger patient safety or influence the completion of the study were not allowed (including but not limited to hypertension, severe diabetes, active infection, thyroid disease, etc.);

12. Patients were not allowed who with inability to swallow, chronic diarrhea and intestinal obstruction, accompany multiple factors affecting the administration and absorption of medicines;

13. Any other circumstances in which the investigator considers the patients unsuitable for participation in the study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Locally Advanced Breast Cancer

Intervention

Drug:
• letrozole
Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy,if don't work, CDK4/6 Inhibitor was added.

Locations

Country	Name	City	State
China	Breast Cancer Center, Shandong Cancer Hospital and Institute	Jinan	Shandong

Sponsors (2)

Lead Sponsor	Collaborator
Yongsheng Wang	Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ki67 index	Independent review committee (IRC) evaluates the Ki67 index after treatment. Ki67 index using the definition of HE stained breast cancer samples after neoadjuvant therapy and surgery. (Defined by the American Joint Committee onCancer, AJCC).	Up to approximately 2 weeks
Secondary	Objective Overall Response Rate	Defined as the proportion of subjects who achieved CR or PR as optimal tumor response during neoadjuvant therapy. Objective response rates will be assessed according to the RECIST v1.1 for the evaluation of efficacy in solid tumors.	Up to approximately 7 weeks